CLINUVEL PHARMACEUTICALS WKN: A0JEGY ISIN: AU000000CUV3 Kürzel: CUV Forum: Aktien Thema: Hauptdiskussion

CLINUVEL PHARMACEUTICALS LTD today released the slides and recording from its Investor Webinar, held on 25 October 2021. The full recording can be accessed on CLINUVEL’s website at  https://news.clinuvel.com/2021/10/26/clinuvel-investor-webinar-october-2021/

FIRST PATIENT TREATED IN CLINUVEL DNA REPAIR STUDY Xeroderma pigmentosum (XP) patient dosed with afamelanotide in CUV156 https://www.clinuvel.com/first-patient-treated-in-clinuvel-dna-repair-study/ EXECUTIVE SUMMARY: • Afamelanotide evaluated as DNA repair therapy, photoprotective, in rare disorder XP • First XP patient receives afamelanotide in innovative CUV156 study • CUV156 focus on safety, reduction and repair of DNA damage ...

https://euipo.europa.eu/eSearch/#details/trademarks/018578458

https://www.worldofvalue.de/beitrag/clinuvel-pharmaceuticals-211019

https://hotcopper.com.au/threads/ann-investor-webinar.6355397/ CLINUVEL PHARMACEUTICALS LTD today announced an Investor Webinar shall be held on 25 October 2021. Details of the webinar are provided below: Investor Zoom Webinar 17:00-17:30 AEDT (8:00-8:30 CEST) 25 October 2021 ...

https://www.qualitycompounders.com.au/2021-registration

https://youtu.be/dZqcb0jR3Eo

Findet man übrigens auch alles auf der Homepage von Clinuvel… hab allerdings aktuell nicht die Zeit die Riesen Pamphlete zu lesen, auf den ersten Blick aber au erstmal nix neues gesehen

Annual Report to shareholders https://hotcopper.com.au/documentembed?id=uOMxKKzFkiWRTLKhOROKAxjvSTYP5Am7wBOZo%2BJvke92GA%3D%3D

Notice of Annual General Meeting/Proxy Form https://hotcopper.com.au/documentembed?id=uOMxKKzFkiWRTLKhOROKAxjvSTYP5Am7wBSZo%2BJvke92GA%3D%3D 10. November 2021 Appendix 4G and Corporate Governance Statement https://hotcopper.com.au/documentembed?id=uOMxKKzFkiWRTLKhOROKAxjvSTYP5Am7wBaZo%2BJvke92GA%3D%3D

https://www.clinuvel.com/operations-update-webcast-II/

CLINUVEL Progresses DNA Repair Program https://www.clinuvel.com/clinuvel-progresses-dna-repair-program/ CUV156 study to evaluate the DNA repair effects of SCENESSE® in Xeroderma Pigmentosum (XP) ...today announced that it has received the necessary regulatory and ethics committee approvals to commence a new study in patients with the rare DNA repair disorder Xeroderma Pigmentosum (XP).  ...

https://finance.yahoo.com/news/boao-winhealth-rare-disease-medical-130000712.html

Mal sehen wie sich die Preiserhöhung dann schon durchschlägt

Das nächste größere Event wären dann wohl die Zahlen im Oktober ... die könnten dann die weitere Richtung zeigen. Es sei denn es kommen natürlich vorher noch News zu irgendwas